Vildagliptin dihydrate is used as a selective dipeptidyl peptidase-IV (DPP-IV) inhibitor for the treatment of type 2 diabetes; it enhances plasma active GLP-1 levels, reduces glucose excursions, stimulates insulin secretion, and promotes beta-cell survival by inhibiting apoptosis and promoting cell proliferation.